Posted by Michael Wonder on 12 Feb 2025
OnCusp Therapeutics receives FDA fast track designation for CUSP06 for the treatment of platinum-resistant ovarian cancer
12 February 2025 - OnCusp Therapeutics today announced that the US FDA has granted fast track designation to CUSP06, a cadherin-6 targeting antibody drug conjugate and the company's lead program, for the treatment of patients with platinum-resistant ovarian cancer.
CUSP06 is composed of a proprietary antibody with high cadherin-6 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor).
